top of page
  • Jonathan Poyer

Biotech Capital Market Environment Highlights - Earnings Season Wrapping Up with JNJ and Novartis Acquisitions



The S&P Select Biotech continues to hover above the 50-day moving average, albeit on low volume in the post earnings news vacuum.



M&A Moves:


  • JNJ agreed to buy Proteologix for $850M

  • Novartis met all tender offer considerations to acquire MorphoSys



Week Ending May 17th, 2024:


  • Biotech: 4 Transactions (1 RM, 1 Follow-On, and 2 RDs) totaling just over $400 Million

  • Med Tech: No Current Week Transactions



2024 YTD:


  • 146 Biotech transactions totaling just under $24 Billion v. 2023 YTD: 61 Biotech transactions totaling just under $9 Billion

  • 5 Med Tech transactions totaling just under $700 Million v. 2023 YTD: 6 Med Tech transactions totaling just over $400 Million



Private Transactions:


  • Biotech: 103 US Transactions / 39 European Transactions

  • Med Tech: 55 US Transactions / 24 European Transactions

3 views0 comments

Comments


bottom of page